Treatment of androgen deficiency in the aging male
|
|
- Claude Greer
- 5 years ago
- Views:
Transcription
1 Treatment of androgen deficiency in the aging male The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Although guidelines for androgen replacement therapy for older men have been developed by several groups, the data to support treatment are based on the results of only a small number of clinical trials. It has not been definitively established that the decline in testosterone seen in most aging men results in an androgen deficient state with health-related outcomes that can be improved by androgen therapy. (Fertil Steril 2006;86(Suppl 4): S by American Society for Reproductive Medicine.) Serum testosterone levels decline as men age (1). In a portion of older men (over 50 years), this decline may result in clinical symptoms and signs of androgen deficiency, or andropause. Although guidelines for androgen replacement therapy for older men have been developed by several groups (2, 3), the data to support treatment are based on the results of only a small number of clinical trials. It has not been definitively established that the decline in testosterone seen in most aging men results in an androgen deficient state with health-related outcomes that can be improved by androgen therapy (4). INDICATIONS FOR TREATMENT Symptoms and Signs Symptoms associated with androgen deficiency in the aging male (ADAM) include low libido (with or without erectile dysfunction) (5); decreased strength, energy, or stamina (6); increased irritability or decreased enjoyment of life (7); and alterations in certain components of cognitive function (8). Physical findings that may be due to androgen deficiency include osteopenia/osteoporosis (9), loss of muscle mass (10), increased visceral adiposity (11), testicular atrophy, and gynecomastia. Age-related androgen deficiency may be worsened by significant abdominal obesity that leads to elevated levels of estrogens and sex hormone binding globulin (SHBG) (12), by liver disease or certain medications. Several published validated questionnaires allow assessment of the clinical manifestations of testosterone deficiency in older men (13 15). Laboratory Evaluations Measurement of one of the components of serum testosterone should be a part of the evaluation for androgen deficiency. Testosterone levels should be evaluated only for patients with signs or symptoms of androgen deficiency. Due Education Bulletin Under revision June Received January 12, 2004; revised and accepted January 12, No reprints will be available. Correspondence to: Practice Committee, American Society for Reproductive Medicine, 1209 Montgomery Highway, Birmingham, Alabama to the circadian variation and pulsatile nature of testosterone secretion, blood samples should be taken in the morning. Routine assessment of testosterone levels in all older men is not recommended because treatment of asymptomatic men has not documented benefits. Serum total testosterone is composed of free, albuminbound, and SHBG-bound components. The combination of free testosterone and albumin-bound testosterone is denoted as bioavailable testosterone, which, in epidemiological studies, is the component that best correlates with parameters such as bone mineral density (6), sexual function (16), and cognition (17). However, it is by no means established that bioavailable testosterone represents the effective and clinically relevant fraction of total testosterone for every androgen target organ. Some effects of testosterone may result from its metabolites, such as estradiol in bone and dihydrotestosterone in the prostate. Since SHBG levels increase with age, the decline in serum bioavailable testosterone with normal aging is much greater than for total testosterone. The laboratory assay for serum total testosterone is widely available, but may lead to misclassification of some men who would be considered androgen deficient on the basis of bioavailable or free testosterone levels. However, the accuracy of some methods for the measurement of free testosterone levels has been challenged (18), and bioavailable testosterone assays are not widely available. A recent trend toward measurement of total testosterone and SHBG has emerged, allowing calculation of a free testosterone index (FTI; total testosterone/shbg) as an indication of the amount of bioavailable testosterone. Currently there is no universal consensus on the hormonal and clinical criteria that should be used to identify those older men who are candidates for androgen therapy. The current recommendations are therefore based on expert opinion, and there is an urgent need for additional studies to better elucidate which patients are likely to benefit from androgen therapy. Consensus recommendations from The Endocrine Society indicate that a total testosterone level below 200 ng/dl ( 6.9 nmol/l) indicates hypogonadism and warrants treatment unless contraindicated. Total testosterone levels of 200 to 400 ng/dl ( nmol/l) may suggest therapy could be beneficial, and total testosterone S236 Fertility and Sterility Vol. 86, Suppl 4, November /06/$32.00 Copyright 2006 American Society for Reproductive Medicine, Published by Elsevier Inc. doi: /j.fertnstert
2 levels above 400 ng/dl are unlikely to reflect androgen deficiency (2). Measuring free or bioavailable testosterone or calculating the FTI may be useful in the evaluation of men who might benefit from androgen treatment. Values for bioavailable testosterone that are below the normal range for normal young adult men, or a FTI less than nmol/ nmol, (1) supports the diagnosis of androgen deficiency. A serum LH should be measured as part of the evaluation of an older man with androgen deficiency to detect secondary hypogonadism (of hypothalamic-pituitary origin.) Serum gonadotropin levels rise modestly with age, but few older men have values outside the normal range for young adult men. Further evaluation with serum prolactin and pituitary MRI is warranted when the total testosterone level is very low ( 150 ng/dl, 5.2 nmol/l) and the serum LH is normal or low. DECISION TO TREAT Men over age 50 years should be considered candidates for androgen therapy if they have [1] clinical manifestations indicative of ADAM (osteopenia, decreased muscle mass and strength, decline in stamina and energy, low libido, loss of erectile quality, irritability, impaired cognition, or other mood changes); [2] a low serum testosterone, bioavailable testosterone, or FTI; and [3] no contraindications to treatment. Because the long-term health risks and benefits of androgen therapy for androgen deficiency in the older man have not been defined, it is important to monitor treated patients for both efficacy and safety. At a minimum, physical examination before therapy begins should include the breasts, heart, lungs, and prostate to exclude preexisting gynecomastia, cardiovascular anomalies, or prostatic conditions that may be exacerbated by treatment. A pretreatment serum prostate specific antigen (PSA) and complete blood count also should be obtained. Prostate biopsy is recommended when the digital rectal examination or PSA is abnormal. It is premature to recommend preventive androgen therapy in older men with androgen deficiency. Most older men are relatively hypogonadal and should be considered as candidates for androgen therapy only when they have symptoms or physiological findings that can be reasonably attributed to androgen deficiency. Such physiological findings and symptoms have a complicated pathogenesis and could be affected by a variety of factors. THERAPEUTIC AGENTS AND MONITORING DURING TREATMENT Therapeutic Agents All commercial androgen formulations currently available in the United States are preparations of testosterone, an androgen that can be converted to estradiol. Estradiol may be the major sex steroid affecting male bone density (19). The efficacy of testosterone therapy should be determined on an individual basis. There is no evidence that clinical response FERTILITY & STERILITY differs with the testosterone formulation employed; the benefits of treatment depend on the serum testosterone level that is achieved. Replacement of endogenous testosterone with equivalent levels of exogenous hormone has no measurable effect. The goal of androgen therapy is to raise testosterone levels over pretreatment values without exceeding the normal range for young adult males. No dose-effect of androgen therapy has been demonstrated. Table 1 lists the major testosterone delivery forms available in the United States that are considered safe for use in older men. The oral methylated testosterones are not listed and should not be used because of their potential for liver toxicity. Selection is based on patient preference, the serum testosterone levels that can be obtained, and the potential side effects unique to the testosterone delivery form (Table 1). Dehydroepiandrosterone (DHEA), a progenitor of testosterone and other sex steroids, is commercially available in oral form as an unregulated health supplement. When used in standard replacement doses ( mg/day) in older men, DHEA does not significantly increase serum testosterone levels (20), although higher doses may. No data relating to the efficacy of DHEA for the treatment of androgen deficiency in older men are available. Monitoring During Treatment Within the first two to three months after treatment begins, the older man receiving testosterone therapy should be seen to evaluate the clinical response and to identify possible adverse events. Assessment for weight gain, peripheral edema, gynecomastia, breast tenderness, symptoms of benign prostatic hyperplasia (BPH), problems with sleep, and a digital rectal examination of the prostate should be done. To assess effective administration of the testosterone, a single testosterone level should be measured (see Table 1 for recommended time to assess testosterone level for each replacement modality). Since therapy is empiric, the clinical response may be a better guide than the testosterone level. Some of the same questionnaires available for the initial ADAM evaluation can be used again to monitor relative treatment efficacy (15). Safety monitoring parameters should include a hemoglobin or hematocrit level and serum PSA determination. The PSA level is especially important, because a rapid rise ( 1.0 ng/ml) (27) within the first three to six months of therapy may reflect the presence of a preexisting cancer not previously detected, due to the fact that PSA production is androgen-dependent. Androgen therapy should be discontinued in men who have a significant increase in serum PSA until a complete prostate evaluation can be accomplished. Because there have been no reports of adverse effects on liver function or lipoprotein profiles in older men receiving androgen therapy, such monitoring during treatment is unnecessary for most men. If there are no obvious adverse treatment effects, the serum testosterone level is within the therapeutic range, and S237
3 S238 ASRM Practice Committee Androgen deficiency in the aging male Vol. 86, Suppl 4, November 2006 TABLE 1 Testosterone delivery systems available in the United States. Preparation Initial treatment dose for older men Time to peak testosterone Timing of testosterone testing during treatment Possible specific side effects Injectable esters Testosterone enanthate ( mg every 2 wk or 2 3 d 1 wk Pain at injection site; mood swings mg/cc; 10 cc) 75 mg/wk Testosterone cypionate ( mg every 2 wk or 2 3 d 1 wk Elevated hematocrit mg/cc; 10 cc) 75 mg/wk Testosterone pellets 225 mg/4 6 mo 1 mo 3 4 mo Local site infection; extravasation of pellet; mood swings; elevated hematocrit Patches Scrotal (40 cm 2 ;60cm 2 ; Testoderm) 40 cm 2 ; 1 patch/d 3 5 h 12 h Local site irritation Nonscrotal (2.5 mg or 5 mg; 5 mg/d 6 10 h 12 h Skin irritation; urticaria Androderm, a Testoderm TTS) b Gel (2.5 g, 5 g packet; Testim, c Androgel) d 5 g/d Constant 2 4 wk Occasional mild skin irritation a Androderm (Watson Pharma, Morristown, NJ). b Testoderm TTS (Alza, Mountain View, CA). c Testim (Auxilium, East Norriton, PA). d Androgel (Solvay, Marietta, GA). ASRM Practice Committee. Androgen deficiency in the aging male. Fertil Steril 2006.
4 therapy is judged efficacious, evaluation should be repeated within three months, six months thereafter, and then at least annually. A CBC, serum PSA, and testosterone level should be obtained three and six months after treatment begins, and at least annually thereafter. If osteoporosis was an indication for androgen therapy, bone mineral density should be reevaluated approximately two years after the initiation of treatment. Risks of Treatment The potential risks of androgen therapy in older men include fluid retention, gynecomastia, excessively elevated red blood cell mass, exacerbation of sleep apnea or benign or malignant prostate disease, and an increase in cardiovascular disease (CVD) risk. The fluid retention and gynecomastia are usually mild and occur infrequently for men with testosterone in the normal range. Although new or worsening sleep apnea during testosterone treatment has been observed (21), it appears to be infrequent (22). An increase in red blood cell mass leading to polycythemia also may occur during testosterone therapy in older men. The potential for treatment to aggravate CVD is theoretical and largely based on observations that CVD is more common in men than in age-matched women. However, epidemiological studies have observed that low testosterone levels are more predictive of male CVD than high levels, and other studies have shown that testosterone has arterial vasodilatory (23) and anti-ischemic effects (24). Androgen therapy in older men generally has been shown to improve, rather than worsen, atherosclerotic lipid profiles (2). Better definition of the effects of testosterone treatment on CVD risk awaits the results of large randomized clinical trials. Exacerbation of benign prostatic hyperplasia (BPH) or incident prostate cancer with testosterone treatment is another theoretical concern, although replacement studies performed todate have shown little to no change in PSA (25), no exacerbation of BPH symptoms, and no increased propensity for development of prostate cancer. Nevertheless, experience with androgen therapy in the older man is too limited to allow confident conclusions regarding the long-term prostate risks of treatment (4). Based on potential risks of treatment for androgen deficiency in older men, the absolute contraindications to such therapy are [1] clinical prostate cancer, [2] previous history or current evidence of breast cancer, [3] elevated hematocrit ( 55%), and [4] sensitivity to ingredients in androgen formulations. Relative contraindications to androgen therapy are [1] severe obstructive sleep apnea; [2] hematocrit 52%; [3] severe lower urinary tract symptoms due to benign prostatic hyperplasia (BPH); and [4] medical conditions wherein modest fluid retention may be harmful (example: congestive heart failure). Some evidence suggests that hypogonadal men are at increased risk for unsuspected prostate cancer because their PSA production is falsely suppressed by low androgen levels (26, 27). However, PSA levels in hypogonadal men with cancer are likely to increase rapidly during androgen treatment; therefore, androgen therapy may facilitate detection of prostate cancer with appropriate monitoring. FERTILITY & STERILITY SUMMARY Androgen deficiency in the aging male may be associated with changes in mood, body composition, stamina, energy, and decreased sexual and cognitive function as well as loss of bone mineral density. Testosterone replacement therapy may reverse these signs and symptoms. Only men with signs or symptoms of ADAM should have serum testosterone evaluation. For symptomatic men with low testosterone ( 200 ng/ dl), treatment should be considered. For symptomatic patients with borderline testosterone levels ( ng/dl), free or bioavailable testosterone levels or free testosterone index (FTI) should be evaluated. During treatment, testosterone, PSA, and hematocrit should be monitored, and routine digital rectal examination is recommended. Available data on the benefits and risks of testosterone replacement are limited and do not allow specific treatment recommendations. More randomized clinical trials are needed to evaluate the effects of androgen replacement in aging males. Acknowledgments: This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to their members and other practicing clinicians. While this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. This report was approved by the Board of Directors of the American Society for Reproductive Medicine in December REFERENCES 1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone in healthy men. J Clin Endocrinol Metab 2001;86: Swerdloff RS, chair. Proceedings of the Endocrine Society Andropause Consensus Conferences The Endocrine Society, Continuing Medical Education Series, Morales A, Lunenfeld B. Standards, guidelines, and recommendations of the International Society for The Study of the Aging Male (ISSAM): androgen replacement therapy in aging men with secondary hypogonadism. Aging Male 2001;4: Report of National Institute on Aging advisory panel on testosterone replacement in men. J Clin Endocrinol Metab 2001;86: Korenman SG, Morley JE, Mooradian AD, Davis SS, Kaiser FE, Silver AJ, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab 1990;71: van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationship with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000;85: Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry 1998;155: Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994;108: Greendale G, Edelstein S, Barrett-Connor E. Endogenous sex steroid and bone mineral density in older women and men. The Rancho Bernardo Study. J Bone Miner Res 1997;12: Vermeulen A, Goemaere S, Kaufman JM. Sex hormones, body composition, and aging. Aging Male 1999;2:8 15. S239
5 11. Turner HE, Wass JA. Gonadal function in men with chronic illness. Clin Endocrinol 1997;47: Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, et al. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab 2000;85: Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49: Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocriol 2000;53: Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S. The aging males symptoms rating scale: cultural and linguistic validation into English. Aging Male 2001;4: Nilsson P, Moller L, Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle aged males. J Intern Med 1995;237: Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002;87: Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84: Khosla S, Melton LJ 3rd, Atkinson EJ, O Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men: a key role for bio-available estrogen. J Clin Endocrinol Metab 1998;83: Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78: Matsumoto AM, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol 1985;22: Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84: Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999;100: Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999;83: Tenover JS. Experience with testosterone replacement in the elderly. Mayo Clin Proc 2000;75(Suppl):S Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276: Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003;24: S240 ASRM Practice Committee Androgen deficiency in the aging male Vol. 86, Suppl 4, November 2006
Androgen deficiency in the aging male
Androgen deficiency in the aging male Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology The American Society for Reproductive
More informationOriginal Research Declining testicular function in aging men
(2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationInsight into male menopause'
Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationJeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017
Jeremiah Murphy, MD Mercy Urology Clinic October 21, 2017 Describe an appropriate strategy for the evaluation and diagnosis of male hypogonadism Endocrine Society Clinical Practice Guideline-2010 Review
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review
More informationChapter 5. General discussion
Chapter 5. General discussion 127 Chapter 5 In 2003, two review papers concluded that endogenous androgens do not show any consistent association with cardiovascular disease (CVD) risk 1,2. Apparently,
More informationMI Androgen Deficiency Hypogonadism
MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationAffirming Care of the Transgender Patient
Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute
More informationTestosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More information1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride
1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride
More informationFINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM
750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride
More informationThe Testosterone Quandary. Beth Crowder, PhD, APRN
The Testosterone Quandary Beth Crowder, PhD, APRN Objectives Define testosterone, the hypothalamic-pituitary-gonadotrophic axis, and normal blood levels List functions of testosterone and symptoms of low
More informationMedical Policy Testosterone Therapy
Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet
More informationA mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men
European Journal of Endocrinology (2004) 151 241 249 ISSN 0804-4643 EXPERIMENTAL STUDY A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men Paul
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationClinical Policy: Testosterone Reference Number: AZ.CP.PHAR.02 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.02 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for
More informationAssociate Professor Geoff Braatvedt
Associate Professor Geoff Braatvedt Endocrinologist Diabetologist and Physician Green Lane and Auckland City Hospitals Auckland 14:00-14:55 WS #145: Approach to Low Testosterone Values 15:05-16:00 WS #157:
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL.
Generic Brand HICL GCN Exception/Other ANDRODERM 01403 ROUTE MISCELL. ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO DEPO- 01400 ROUTE MISCELL. CYPIONATE TESTOSTERON E GCN 38586 DELATESTRYL 01401
More informationPRODUCT INFORMATION PROVIRON
PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5
More informationInappropriate Testosterone Billings
Inappropriate Testosterone Billings Carla Patrick-Fagan March 30, 2015 Truven Health Analytics Inc. All Rights Reserved. 1 Agenda Proposed in the 2015 analytic plan Steroid prescriptions Code of Federal
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationSeptember 17, FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT):
JOINT MEETING FOR BONE, REPRODUCTIVE AND UROLOGIC DRUGS ADVISORY COMMITTEE (BRUDAC) AND THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE (DSARM AC) September 17, 2014 FDA background documents for
More informationThe Science of. NUTRICULA Longevity Journal
32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,
More informationFINCAR Tablets (Finasteride)
Published on: 10 Jul 2014 FINCAR Tablets (Finasteride) Composition FINCAR Tablets Each film-coated tablet contains: Finasteride USP - 5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of
More informationLong-term experience with testosterone replacement through scrotal skin
CHAPTER 13 1 Long-term experience with testosterone replacement through scrotal skin Linda E. Atkinson, Yu-Lin Chang, and Peter J. Snyder Contents 13.1 13.1.1 13.1.2 13.2 13.2.1 13.2.2 13.2.2.1 13.2.2.2
More informationAll About T Testosterone for FTMs. Presented by John Otto, MLIS
All About T Testosterone for FTMs Presented by John Otto, MLIS Who? Anyone thinking about transitioning Those who have transitioned, but want to know more Empowerment from self-managing transition Allies
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationXYOSTED (testosterone enanthate) injection, for subcutaneous use CIII Initial US approval: 1953 IMPORTANT SAFETY INFORMATION
ANTARES PHARMA ANNOUNCES THE COMMERCIAL AVAILABILITY OF XYOSTED (TESTOSTERONE ENANTHATE) INJECTION A NEW TREATMENT FOR ADULT MEN DIAGNOSED WITH TESTOSTERONE DEFICIENCY XYOSTED - A Novel Subcutaneous Testosterone
More informationOF THE one thousand generations of humans that have
0021-972X/98/$03.00/0 Vol. 83, No. 10 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society THERAPEUTIC PERSPECTIVE Issues in Testosterone Replacement
More informationMedication Policy Manual
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Non-preferred, non-transdermal testosterone replacement therapy products (Android, Aveed, Androxy, Methitest,
More informationMonth/Year of Review: September 2013 Date of Last Review: December 2009
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2013 Oregon State University. All Rights
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationPackage Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)
Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationTestosterone as a Therapeutic Tool
330 Medicine Update 56 Testosterone as a Therapeutic Tool SV MADHU INTRODUCTION Testosterone preparations have been available for many years and have been used by physicians primarily to treat sexual problems.
More informationDr Tarza Jamal Pharmacology Lecture 2
Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationPros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery
Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery David T Zava, PhD ZRT laboratory A Guide to Steroid Hormone Testing in Different Body Fluids Following
More informationMale Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2
Male Hormone Replacement Therapy Punita Dhindsa D.O PGY 2 Physiology of Testosterone & Causes of Hypogonadism in Males The use of testosterone therapy is very common in the US, with an estimated 2.3 million
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationSUMMARY and OBJECTIVES. LOW T- I m half the man I used to be. Prevalence of Low-T. Definition of Hypogonadism 9/19/ Million men in the US
SUMMARY and OBJECTIVES LOW T- I m half the man I used to be A discussion of male hypogonadism David Doriguzzi, PA-C Valley Endocrine & Diabetes Consultants Definition Prevalence Causes Signs & Symptoms
More informationReproductive DHT Analyte Information
Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone
More informationDUPROST Capsules (Dutasteride)
Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride
More informationMonitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc.
Mr Mark Newman Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. 2 Avoiding Pitfalls in (B)HRT Monitoring and Picking the Right Lab Test Objectives: Outline how expected
More informationThe physiology of normal androgen production in
Mayo Clin Proc, April 2004, Vol 79 (Supplement) Formulations and Use of Androgens S3 Supplement Article Formulations and Use of Androgens in Women MICHELINE C. CHU, MD, AND ROGERIO A. LOBO, MD The physiology
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women s logo is placed throughout
More informationMens Health Post Puberty. Nayan Patel PharmD
Mens Health Post Puberty Nayan Patel PharmD Definition of Androgen Deficiency * Consistently low testosterone * Associated signs/symptoms * Evidence based review of literature * Data is weak at best Definition
More informationAlthough women produce only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Mary Lake Polan, MD, PhD, MPH Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Chair Emeritus,
More informationPRODUCT INFORMATION. Testosterone Phenylpropionate: Testosterone Phenylpropionate is 3-oxoandrost-4-en-17β-yl
PRODUCT INFORMATION SUSTANON '250' NAME OF THE MEDICINE Sustanon '250' ('250' mg/ml for injection): testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate.
More informationAndroGel. (testosterone gel) 1% H 3 C
1 AndroGel (testosterone gel) 1% 500122/500127 Rev Dec 2004 DESCRIPTION AndroGel (testosterone gel) is a clear, colorless hydroalcoholic gel containing 1% testosterone. AndroGel provides continuous transdermal
More informationNew long-acting androgens
World J Urol (2003) 21: 306 310 DOI 10.1007/s00345-003-0364-x TOPIC PAPER Louis J. Gooren New long-acting androgens Received: 16 September 2003 / Accepted: 17 September 2003 / Published online: 9 October
More informationTestim 1% PRODUCT MONOGRAPH. (testosterone gel) Androgens. Paladin Labs Inc. 100 Alexis Nihon Blvd., Suite 600 St. Laurent, Quebec H4M 2P2
PRODUCT MONOGRAPH C Testim 1% (testosterone gel) Androgens Paladin Labs Inc. 100 Alexis Nihon Blvd., Suite 600 St. Laurent, Quebec H4M 2P2 Date of Revision: February 3, 2017 Control No: 201331-1 - Table
More informationAS our population ages, concerns about frailty and
Journal of Gerontology: MEDICAL SCIENCES 2004, Vol. 59A, No. 5, 461 465 Copyright 2004 by The Gerontological Society of America Special Article Masculine Vitality: Pros and Cons of Testosterone in Treating
More informationTESTIM (testosterone gel) for topical use, CIII Initial U.S. Approval: 1953
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTIM safely and effectively. See full prescribing information for TESTIM. TESTIM (testosterone
More information4.2 Posology, method and duration of administration
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in May 2011. 1. NAME OF MEDICINAL PRODUCT Testoviron Depot Oily solution for injection
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Implantable Hormone Pellets Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...
More informationAndropause How Relevant?
Andropause How Relevant? 323 55 Andropause How Relevant? VN MISHRA, NALINI MISHRA INTRODUCTION In day-to-day practice it is not unusual to encounter male patients in their 50s or older who come to physician
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication o 50 mg/0.5 ml. Revised: 09/2018 o 100 mg/0.5 ml
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XYOSTED safely and effectively. See full prescribing information for XYOSTED. XYOSTED (testosterone
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 53 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationMale hypogonadism is a clinical syndrome that
Journal of Andrology, Vol. 33, No. 4, July/August 2012 Copyright E American Society of Andrology A Novel Testosterone 2% Gel for the Treatment of Hypogonadal Males ADRIAN S. DOBS,* JOHN MCGETTIGAN,{ PAUL
More informationGonadal Steroids and Body Composition, Strength, and Sexual Function in Men
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men Joel S. Finkelstein, M.D., Hang Lee, Ph.D., Sherri-Ann
More informationUpdates on Anti-doping and TUE Management in Paralympic Sport
International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops
More informationHypogonadism and Testosterone Replacement Therapy
Testosterone Replacement Therapy Hypogonadism and Testosterone Replacement Therapy a report by Adrian S Dobs, MD, MHS and Anjana Myneni, MD Professor of Medicine and Oncology, Department of Medicine, Johns
More informationCinryze. Cinryze (C1 esterase inhibitor [human]) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.05 Subject: Cinryze Page: 1 of 5 Last Review Date: September 20, 2018 Cinryze Description Cinryze
More informationRisks and benefits of testosterone therapy in older men. Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin
Risks and benefits of testosterone therapy in older men Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin Abstract In young men (defined as age
More informationAre Steroids Worth the Risk?
Are Steroids Worth the Risk? Dominic has baseball on the brain. Just being good isn't enough he wants to be the best. He dreams of playing in the majors someday, but worries about the intense competition
More informationGynaecomastia. Benign breast conditions information provided by Breast Cancer Care
Gynaecomastia This booklet tells you about gynaecomastia. It explains what gynaecomastia is, what causes it, how it s diagnosed and what will happen if it needs to be treated or followed up. Benign breast
More informationPersistent depression? Low libido?
Persistent depression? Low libido? 24 Androgen decline may be to blame Cyril decommarque / Photonica Low serum testosterone can often be corrected without using hormones, such as by changing or supplementing
More informationPRESCRIBING INFORMATION
PRESCRIBING INFORMATION C DELATESTRYL* testosterone enanthate Solution for Injection, 200 mg/ml Androgens Valeant Canada LP 2150 Blvd. St-Elzear West Laval, Quebec H7L 4A8 Date of Revision: August 19,
More informationThe Current Status of Therapy for Symptomatic Late-Onset Hypogonadism withtransdermal Testosterone Gel
European Urology European Urology 47 (2005) 137 146 Review The Current Status of Therapy for Symptomatic Late-Onset Hypogonadism withtransdermal Testosterone Gel T. Ebert a,1, F. Jockenhövel b,2, A. Morales
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use testosterone gel safely and effectively. See full prescribing information for testosterone gel. Testosterone
More informationIf looking for a book Testosterone: Boost Testosterone Naturally - For - Weight Loss, Muscle Building, Libido & Erectile Dysfunction (Testosterone
Testosterone: Boost Testosterone Naturally - For - Weight Loss, Muscle Building, Libido & Erectile Dysfunction (Testosterone Enanthate, Testosterone Replacement... Pressure, Tongkat Ali, Increase Testo)
More informationANDROGENS PLAY AN essential role in the sexual
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone
More informationTESTOSTERONE gel, for topical use, CIII Initial U.S. Approval: 1953
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTOSTERONE gel safely and effectively. See full prescribing information for TESTOSTERONE gel. TESTOSTERONE
More informationPRODUCT MONOGRAPH ANDROGEL. Testosterone gel. Androgens
PRODUCT MONOGRAPH ANDROGEL Testosterone gel 1% Androgens BGP Pharma ULC 85 Advance Road Etobicoke, Ontario M8Z 2S6 Date of Preparation: December 19, 2014 Date of Previous Revision: August 27, 2015 Date
More informationRelationship between Aerobic Training and Testosterone Levels in Male Athletes
Relationship between Aerobic Training and Testosterone Levels in Male Athletes Siu Yuen Ng Biology 493 13 th December, 2010 Abstract Salivary testosterone levels of 11 athletes and 15 non athletes were
More informationTransgender 201: Case Discussion Group
Transgender 201: Case Discussion Group Melissa Davis, MD Maria Barnett, DO October 19, 2017 Maria Barnett, DO, Date Welcome! Disclosures Introductions Discussion The total time of this workshop will depend
More informationThis is an English translation of the original Chinese instruction leaflet generated by Google Translate. No amendments were made.
Approved Date: December 26, 2006 Revision Date: September 12, 2012 Modify Date: December 1, 2013 Finasteride tablets instructions Please read the instructions carefully and use under the guidance of a
More informationInitial trial of slow-release testosterone microspheres in hypogonadal men*
FERTILITY AND STERILITY Copyright c 1988 The American Fertility Society Printed in U.S.A. Initial trial of slow-release testosterone microspheres in hypogonadal men* Allen S. Burris, M.D. t Larry L. Ewing,
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s International Pharmacy staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women
More information